Company Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.
The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1990 |
| IPO Date | May 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Howard Robin |
Contact Details
Address: 455 Mission Bay Boulevard South San Francisco, California 94158 United States | |
| Phone | 415 482 5300 |
| Website | nektar.com |
Stock Details
| Ticker Symbol | NKTR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000906709 |
| CUSIP Number | 640268306 |
| ISIN Number | US6402683063 |
| Employer ID | 94-3134940 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard W. Robin | Chief Executive Officer, President and Director |
| Dr. Jonathan Zalevsky Ph.D. | Senior Vice President and Chief Research and Development Officer |
| Linda M. Rubinstein M.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Jason Barnard | Chief Accounting Officer |
| Elizabeth Zhang | Vice President of Legal, Corporate Counsel and Secretary |
| Robert Bacci | Chief People Officer and Head of Quality and Facilities |
| Jennifer Ruddock | Chief Business Officer |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer |
| Dr. Ken Franke Ph.D. | Senior Vice President of Biologics Process Development and Manufacturing |
| Charleen Jue | Senior Vice President of Clinical Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 144 | Filing |
| Jun 16, 2026 | 144 | Filing |
| Jun 15, 2026 | 144 | Filing |
| Jun 5, 2026 | 8-K | Current Report |
| May 19, 2026 | 144 | Filing |
| May 19, 2026 | 144 | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | 424B5 | Filing |
| May 8, 2026 | 8-K | Current Report |
| May 8, 2026 | 10-Q | Quarterly Report |